RF Acquisition Corp II - Unit (RFAIU)

On our desk, the reaction to the August 19, 2026 shareholder vote approving the Nanyang Biologics merger was nothing short of electric. RFAI and its associated units saw immediate buying pressure, exploding past 200% to 360% gains in single sessions. Sentiment across retail and micro-cap channels flipped aggressively positive as filing updates confirmed the combination. We are monitoring liquidity closely as prices push toward the $58 intraday ceiling.

When evaluating how structural components like units consisting of 1 ordinary share and 1 right behave during a major business combination, RFAIU provides a textbook case study. The separation of ordinary shares and rights that began back in mid-2022 set the stage for this exact type of post-approval rerating. Analysts must examine how rights convert and scale relative to the newly vaulted common equity prices.

From a risk management standpoint, trading an unmoored SPAC post-merger approval requires strict position sizing. While historical trust redemption values hovered around $11.24 back in late 2024, the current market pricing above $51 reflects absolute post-combination euphoria following the Nanyang Biologics vote. Gamma and momentum are currently driving all price action, completely decoupling the asset from its original blank check fundamentals.

Watching the order flow on Benzinga and RTTNews reports regarding the Nanyang Biologics merger approval, retail FOMO has clearly entered the chat. With shares and units trading up past 300% to roughly $51.76 on heavy relative volume, community sentiment metrics have maxed out. However, traders need to be wary of sharp mean-reversion pullbacks after such vertical moves.

Looking at the SEC Form 8-K filings dated August 12, 2026, and the subsequent August 19 meeting results, the legal mechanics of the Nanyang Biologics combination went off without a hitch. Our quantitative models flagged the sudden volume expansion as soon as the shareholder vote was finalized, validating our breakout triggers on high-beta SPAC combinations.